Looming workforce issues in rheumatology are not unique to the United States. Health care systems around the world are looking at various models to address potential gaps in care for patients with rheumatic diseases.

As important as research results may be, just as important is effectively communicating those results to peers, colleagues, and the broader scientific community. Properly designed visual aids, such as graphs and tables, can be essential in getting the message across.

New data on the pathways leading to kidney injury in lupus nephritis suggest new therapeutic targeting approaches that may limit renal damage.

Checkpoint inhibitor therapy has emerged as a frontline immunotherapy cancer treatment, but cancer immunotherapy results in both characteristic organ-specific autoimmunity and idiosyncratic autoimmune reactions. Rheumatologists are being increasingly called upon to treat these patients with immunosuppressive therapy.

Monday ACR session will review the use of ultrasonography and MRI in the assessment of pediatric rheumatic diseases and the potential benefits of each modality in a treat-to-target approach.

Clinical trials offer benefits to patients and providers, but getting started as a principal investigator can be a daunting task for physicians.

What once was not given much thought by many is becoming seen as increasingly important and as a sough-after career path for more aspiring physicians.

Phototherapy, a familiar therapeutic treatment modality in dermatology, may be coming to rheumatology.

Although initiatives to increase awareness, improve care, and conduct research are making some inroads in Africa, there remains a dearth of information on rheumatic and musculoskeletal diseases in Africa.

New findings about myositis, including new classification and diagnostic criteria along with new data on overlap with other autoimmune conditions, is changing the ways clinicians assess and manage the disease.